Although the effectiveness of PD-(L)1 blockade was recently improved by its combination with Vascular endothelial growth factor (VEGF) receptor inhibitors or CTLA4 checkpoint blockade (11), ORRs remain lower than 30% and suggested to be particularly low in nonalcoholic steatohepatitis (NASH)-related HCC (12, –14). This evidence concerns the gene VEGFA and metabolic dysfunction-associated steatohepatitis.